We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Technology Combines Speed of Rapid Antigen Test with Accuracy of PCR Testing to Detect COVID-19 in 4 Minutes

By LabMedica International staff writers
Posted on 10 Feb 2022
Print article
Illustration
Illustration

Scientists have developed a new coronavirus test that is accurate as a polymerase chain reaction (PCR) lab test but gives results within four minutes.

The test developed by researchers at Fudan University (Shanghai, China) uses a hypersensitive electromechanical biosensor to detect nucleic acids that were earlier difficult to identify owing to their low concentration in test samples. The sensor which uses microelectronics to analyze genetic material from swabs could reduce the need for time-consuming lab tests for diagnosing COVID-19.

PCR tests are the most accurate and sensitive for detecting SARS-COV-2, the virus that causes COVID-19, although they can take several hours to deliver results. Rapid antigen tests are a quicker alternative and deliver results in 15 minutes but are less reliable than PCR tests which are more accurate due to their greater sensitivity. In comparison to PCR tests, antigen tests require a higher concentration of the virus to exhibit a positive result due to which they are more likely to show a false negative. Antigen tests look for pieces of virus-infected proteins, while PCR tests search for viral genetic material such as nucleic acids and RNA.

Currently, there is no technology that can properly detect COVID-infected nucleic acids and RNA without using extraction and amplification methods which require a lab environment. The new method that uses a hypersensitive electromechanical biosensor to detect nucleic acids offers speed, ease of operation, high sensitivity and portability. Portable tests based on this technology could be used for on-site COVID-19 testing at airports, clinics, emergency departments and at home, as well as for quickly diagnosing other types of diseases.

In a clinical trial of the new test, the researchers collected nasal samples from 33 PCR-positive COVID-19 patients, 23 PCR-negative patients, six influenza-positive patients and 25 healthy volunteers. The researchers found that the test accurately processed all the cases without any errors in less than four minutes. The trial was conducted on a small sample, and if the 100% accuracy rate was replicated in a larger test sample, then the new test could be a game changer in COVID-19 diagnosis.

"We implemented an electromechanical biosensor for the detection of SARS-CoV-2 into an integrated and portable prototype device, and show that it detected (virus RNA) in less than four minutes," the team said in a peer-reviewed article describing their molecular electromechanical system, or MolEMS, in the journal Nature Biomedical Engineering.

Related Links:
Fudan University 

Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.